Company intelligence / Profile preview

Berg Morris

Framingham, Massachusetts, United Statesaugustberg.com ↗

Ownership: Private
Development stage: Other

Overview

BERG developed an AI-driven drug discovery platform and advanced several programs into the clinic. Its lead asset BPM 31510 received orphan drug designation for pancreatic cancer and epidermolysis bullosa. BPM 31543 completed a Phase I trial for chemotherapy-induced alopecia showing safety and some efficacy. The company also developed diagnostics validated clinically for prostate cancer and other indications.

Therapeutic areas: HematologyNeurologyOncology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

Boehringer Ingelheim – biomarker research collaboration on inflammatory conditions

Beyond the preview

Go deeper on Berg Morris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berg Morris.

Explore the full profile